{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:28:27Z","timestamp":1773185307944,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10067-020-05074-8","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T09:02:48Z","timestamp":1590570168000},"page":"3685-3691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Fragility fractures in psoriatic arthritis patients: a matched retrospective cohort study"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0927-6383","authenticated-orcid":false,"given":"Luciano F.","family":"Lo Giudice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0542-8001","authenticated-orcid":false,"given":"Marina","family":"Scolnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9781-9535","authenticated-orcid":false,"given":"Florencia S.","family":"Pierini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2957-3617","authenticated-orcid":false,"given":"Nicolas M.","family":"Marin Zucaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3464-9276","authenticated-orcid":false,"given":"John F.","family":"Jaramillo Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-1084","authenticated-orcid":false,"given":"Enrique R.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"5074_CR1","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"CL Christiansen","year":"2009","unstructured":"Christiansen CL, Johnston C, Kanis JA et al (2009) Perspective. The diagnosis of osteoporosis The Diagnosis of Osteoporosis. J Bone Miner Res 9:1137\u20131141. https:\/\/doi.org\/10.1002\/jbmr.5650090802","journal-title":"J Bone Miner Res"},{"key":"5074_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3899\/jrheum.120240","volume":"39","author":"A Del Puente","year":"2012","unstructured":"Del Puente A, Esposito A, Parisi A et al (2012) Osteoporosis and psoriatic arthritis. J Rheumatol 39:36\u201338. https:\/\/doi.org\/10.3899\/jrheum.120240","journal-title":"J Rheumatol"},{"key":"5074_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00198-009-1135-3","volume":"21","author":"A Wittich","year":"2010","unstructured":"Wittich A, Bagur A, Mautalen C, Cristofari A, Escobar O, Carrizo G, Oliveri B (2010) Epidemiology of hip fracture in Tucuman, Argentina. Osteoporos Int 21:1803\u20131807. https:\/\/doi.org\/10.1007\/s00198-009-1135-3","journal-title":"Osteoporos Int"},{"key":"5074_CR4","first-page":"55","volume":"73","author":"L Schurman","year":"2013","unstructured":"Schurman L, Bagur A, Claus-Hermberg H et al (2013) Guidelines for the diagnosis, prevention and treatment of osteoporosis, 2012 [Gu\u00edas 2012 para el diagn\u00f3stico, la prevenci\u00f3n y el tratamiento de la osteoporosis]. Med 73:55\u201374","journal-title":"Med"},{"key":"5074_CR5","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00198-005-1839-y","volume":"16","author":"M Morosano","year":"2005","unstructured":"Morosano M, Masoni A, S\u00e1nchez A (2005) Incidence of hip fractures in the city of Rosario, Argentina. Osteoporos Int 16:1339\u20131344. https:\/\/doi.org\/10.1007\/s00198-005-1839-y","journal-title":"Osteoporos Int"},{"key":"5074_CR6","unstructured":"Claus-Hermberg H, Bullrich MPL (2008) Incidencia de Fractura De Cadera en Mujeres Afiliadas al plan M\u00e9dico del Hospital Alem\u00e1n, Buenos Aires. Actual Osteol 4(2):57\u201362"},{"key":"5074_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/BF01622193","volume":"4","author":"A Bagur","year":"1994","unstructured":"Bagur A, Mautalen C, Rubin Z (1994) Epidemiology of hip fractures in an urban population of central Argentina. Osteoporos Int 4:332\u2013335. https:\/\/doi.org\/10.1007\/BF01622193","journal-title":"Osteoporos Int"},{"key":"5074_CR8","doi-asserted-by":"publisher","unstructured":"Harvey NC, Curtis EM, Dennison EM, Cooper C (2018) The epidemiology of osteoporotic fractures. Prim Metab Bone Dis Disord Miner Metab 398\u2013404. https:\/\/doi.org\/10.1002\/9781119266594.ch50","DOI":"10.1002\/9781119266594.ch50"},{"key":"5074_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00198-008-0657-4","volume":"20","author":"P Clark","year":"2009","unstructured":"Clark P, Cons-Molina F, Deleze M, Ragi S, Haddock L, Zanchetta JR, Jaller JJ, Palermo L, Talavera JO, Messina DO, Morales-Torres J, Salmeron J, Navarrete A, Suarez E, P\u00e9rez CM, Cummings SR (2009) The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American vertebral osteoporosis study (LAVOS). Osteoporos Int 20:275\u2013282. https:\/\/doi.org\/10.1007\/s00198-008-0657-4","journal-title":"Osteoporos Int"},{"key":"5074_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bone.2015.05.024","volume":"80","author":"SR Goldring","year":"2015","unstructured":"Goldring SR (2015) Inflammatory signaling induced bone loss. Bone 80:143\u2013149. https:\/\/doi.org\/10.1016\/j.bone.2015.05.024","journal-title":"Bone"},{"key":"5074_CR11","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1136\/annrheumdis-2016-210441","volume":"76","author":"A Ogdie","year":"2017","unstructured":"Ogdie A, Harter L, Shin D, Baker J, Takeshita J, Choi HK, Love TJ, Gelfand JM (2017) The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. Ann Rheum Dis 76:882\u2013885. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210441","journal-title":"Ann Rheum Dis"},{"key":"5074_CR12","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.3899\/jrheum.141112","volume":"42","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian dermatology-rheumatology comorbidity initiative. J Rheumatol 42:1767\u20131780. https:\/\/doi.org\/10.3899\/jrheum.141112","journal-title":"J Rheumatol"},{"key":"5074_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.bone.2008.12.028","volume":"44","author":"I Ghozlani","year":"2009","unstructured":"Ghozlani I, Ghazi M, Nouijai A, Mounach A, Rezqi A, Achemlal L, Bezza A, el Maghraoui A (2009) Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 44:772\u2013776. https:\/\/doi.org\/10.1016\/j.bone.2008.12.028","journal-title":"Bone"},{"key":"5074_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1365-4632.2010.04600.x","volume":"50","author":"EAS Attia","year":"2011","unstructured":"Attia EAS, Khafagy A, Abdel-Raheem S, Fathi S, Saad AA (2011) Assessment of osteoporosis in psoriasis with and without arthritis: correlation with disease severity. Int J Dermatol 50:30\u201335. https:\/\/doi.org\/10.1111\/j.1365-4632.2010.04600.x","journal-title":"Int J Dermatol"},{"key":"5074_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar3240","volume":"13","author":"PG Pedreira","year":"2011","unstructured":"Pedreira PG, Pinheiro MM, Szejnfeld VL (2011) Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis. Arthritis Res Ther 13:1\u20137. https:\/\/doi.org\/10.1186\/ar3240","journal-title":"Arthritis Res Ther"},{"key":"5074_CR16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10067-007-0725-8","volume":"27","author":"P Borman","year":"2008","unstructured":"Borman P, Babao\u011flu S, Gur G, Bingol S, Bodur H (2008) Bone mineral density and bone turnover in patients with psoriatic arthritis. Clin Rheumatol 27:443\u2013447. https:\/\/doi.org\/10.1007\/s10067-007-0725-8","journal-title":"Clin Rheumatol"},{"key":"5074_CR17","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/jid.2008.432","volume":"129","author":"J Dreiher","year":"2009","unstructured":"Dreiher J, Weitzman D, Cohen AD (2009) Psoriasis and osteoporosis: a sex-specific association. J Invest Dermatol 129:1643\u20131649. https:\/\/doi.org\/10.1038\/jid.2008.432","journal-title":"J Invest Dermatol"},{"key":"5074_CR18","doi-asserted-by":"publisher","unstructured":"Taylor W, Gladman D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. 54:2665\u20132673. https:\/\/doi.org\/10.1002\/art.21972","DOI":"10.1002\/art.21972"},{"key":"5074_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/RHU.0b013e31820e7e8d","volume":"17","author":"JE Rosa","year":"2011","unstructured":"Rosa JE, Soriano ER, Narvaez-Ponce L, del Cid C, Imamura PM, Catoggio LJ (2011) Incidence and prevalence of systemic sclerosis in a healthcare plan in Buenos Aires. J Clin Rheumatol 17:59\u201363. https:\/\/doi.org\/10.1097\/RHU.0b013e31820e7e8d","journal-title":"J Clin Rheumatol"},{"key":"5074_CR20","doi-asserted-by":"publisher","unstructured":"Ross PD (1997) Clinical consequences of vertebral fractures. https:\/\/doi.org\/10.1016\/s0002-9343(97)90025-5","DOI":"10.1016\/s0002-9343(97)90025-5"},{"key":"5074_CR21","doi-asserted-by":"publisher","unstructured":"Gehlbach SH, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood JR (2000) International original article recognition of vertebral fracture in a clinical setting. https:\/\/doi.org\/10.1007\/s001980070078","DOI":"10.1007\/s001980070078"},{"key":"5074_CR22","doi-asserted-by":"publisher","unstructured":"Fink HA, Milavetz DL, Palermo L et al (2005) What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? 20:1216\u20131222. https:\/\/doi.org\/10.1359\/JBMR.050314","DOI":"10.1359\/JBMR.050314"},{"key":"5074_CR23","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s10067-013-2322-3","volume":"32","author":"M Riesco","year":"2013","unstructured":"Riesco M, Manzano F, Font P, Garc\u00eda A, Nolla JM (2013) Osteoporosis in psoriatic arthritis: an assessment of densitometry and fragility fractures. Clin Rheumatol 32:1799\u20131804. https:\/\/doi.org\/10.1007\/s10067-013-2322-3","journal-title":"Clin Rheumatol"},{"key":"5074_CR24","doi-asserted-by":"publisher","unstructured":"Heinlen L, Humphrey MB (2017) Skeletal complications of rheumatoid arthritis. https:\/\/doi.org\/10.1007\/s00198-017-4170-5","DOI":"10.1007\/s00198-017-4170-5"},{"key":"5074_CR25","doi-asserted-by":"publisher","unstructured":"Zerbini CAF, Clark P, Pereira RMR, Messina OD (2016) Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-016-3769-2","DOI":"10.1007\/s00198-016-3769-2"},{"key":"5074_CR26","doi-asserted-by":"publisher","unstructured":"Mohamed RH, Mohamed RH (2016) Gene polymorphisms with osteoporosis. 00:1\u20136. https:\/\/doi.org\/10.1089\/gtmb.2015.0227","DOI":"10.1089\/gtmb.2015.0227"},{"key":"5074_CR27","doi-asserted-by":"publisher","unstructured":"Dougados M (2016) Comorbidities in rheumatoid arthritis. 28:282\u2013288. https:\/\/doi.org\/10.1097\/BOR.0000000000000267","DOI":"10.1097\/BOR.0000000000000267"},{"key":"5074_CR28","doi-asserted-by":"publisher","unstructured":"Roux C (2011) Osteoporosis in inflammatory joint diseases. 421\u2013433. https:\/\/doi.org\/10.1007\/s00198-010-1319-x","DOI":"10.1007\/s00198-010-1319-x"},{"key":"5074_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.bone.2017.06.020","volume":"103","author":"R Sapir-koren","year":"2017","unstructured":"Sapir-koren R, Livshits G (2017) Postmenopausal osteoporosis in rheumatoid arthritis : the estrogen deficiency-immune mechanisms link. Bone 103:102\u2013115. https:\/\/doi.org\/10.1016\/j.bone.2017.06.020","journal-title":"Bone"},{"key":"5074_CR30","doi-asserted-by":"publisher","unstructured":"Roubille C, Rincheval N, Dougados M et al (2017) Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis : data from the ESPOIR cohort. 1797\u20131802. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210135","DOI":"10.1136\/annrheumdis-2016-210135"},{"key":"5074_CR31","doi-asserted-by":"publisher","unstructured":"Koehnke R, Caldwell JR, Brasington R et al (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. 96:115\u2013123. https:\/\/doi.org\/10.1016\/0002-9343(94)90131-7","DOI":"10.1016\/0002-9343(94)90131-7"},{"key":"5074_CR32","doi-asserted-by":"publisher","unstructured":"Briot K, Roux C (2015) Glucocorticoid-induced osteoporosis. https:\/\/doi.org\/10.1136\/rmdopen-2014-000014","DOI":"10.1136\/rmdopen-2014-000014"},{"key":"5074_CR33","doi-asserted-by":"publisher","unstructured":"Klop C, Vries F De, Bijlsma JWJ, et al (2016) Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density. 2095\u20132100. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208958","DOI":"10.1136\/annrheumdis-2015-208958"},{"key":"5074_CR34","doi-asserted-by":"publisher","unstructured":"Love T, Haynes K, Shin D, et al (2013) Original article prevalence and treatment patterns of psoriatic arthritis in the UK. 568\u2013575. https:\/\/doi.org\/10.1093\/rheumatology\/kes324","DOI":"10.1093\/rheumatology\/kes324"},{"key":"5074_CR35","doi-asserted-by":"publisher","unstructured":"Van Der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkman BA, van der Horst-Bruinsma I (2018) High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis : a systematic review. 1529\u20131535. https:\/\/doi.org\/10.1007\/s10067-012-2018-0","DOI":"10.1007\/s10067-012-2018-0"},{"key":"5074_CR36","doi-asserted-by":"publisher","unstructured":"Davey-ranasinghe N, Deodhar A (2013) Osteoporosis and vertebral fractures in ankylosing spondylitis. 509\u2013516. https:\/\/doi.org\/10.1097\/BOR.0b013e3283620777","DOI":"10.1097\/BOR.0b013e3283620777"},{"key":"5074_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00223-017-0274-3","volume":"101","author":"C Pray","year":"2017","unstructured":"Pray C, Irene N, Nisha F, Haroon N (2017) Bone mineral density and fracture risk in Ankylosing spondylitis : a meta-analysis. Calcif Tissue Int 101:182\u2013192. https:\/\/doi.org\/10.1007\/s00223-017-0274-3","journal-title":"Calcif Tissue Int"},{"key":"5074_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2219","volume":"9","author":"H Marotte","year":"2007","unstructured":"Marotte H, Pallot-Prades B, Grange L et al (2007) A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 9:1\u20137. https:\/\/doi.org\/10.1186\/ar2219","journal-title":"Arthritis Res Ther"},{"key":"5074_CR39","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/rheumatology\/kei082","volume":"44","author":"U Lange","year":"2005","unstructured":"Lange U, Teichmann J, M\u00fcller-Ladner U, Strunk J (2005) Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-\u03b1 antibody: a prospective open-label pilot study. Rheumatology 44:1546\u20131548. https:\/\/doi.org\/10.1093\/rheumatology\/kei082","journal-title":"Rheumatology"},{"key":"5074_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/ard.2008.091611","volume":"68","author":"CA Wijbrandts","year":"2009","unstructured":"Wijbrandts CA, Klaasen R, Dijkgraaf MGW, Gerlag DM, van Eck-Smit B, Tak PP (2009) Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 68:373\u2013376. https:\/\/doi.org\/10.1136\/ard.2008.091611","journal-title":"Ann Rheum Dis"},{"key":"5074_CR41","doi-asserted-by":"publisher","unstructured":"Kawai VK, Grijalva CG, Arbogast PG et al (2014) Autoimmune diseases. 65:1085\u20131094. https:\/\/doi.org\/10.1002\/acr.21937.Initiation","DOI":"10.1002\/acr.21937.Initiation"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05074-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05074-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05074-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T23:58:04Z","timestamp":1622073484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05074-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5074"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05074-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"3 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"- Lo Giudice M.D., Marin Zucaro M.D., Pierini M.D., and Jaramillo Gallego M.D. declare no conflicts of interest.- Scolnik M.D.: has received in the past speaker fee\/advisory from AbbVie, Pfizer, Roche, Eli Lilly, Bristol MS, Glaxo Smith Kline.- Soriano M.D.: has received in the past speaker\u2019s honorarium from AbbVie, Novartis, Bristol MS, Novartis, Eli Lilly, Genzyme, Pfizer, Amgen, and Roche. He is on the advisory board for Novartis, AbbVie, Pfizer, Eli Lilly, Sanofi, Sandoz, Amgen. He has received grant from Roche, Novartis, AbbVie, Glaxo Smith Kline.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}